Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Kura Oncology, Inc. (KURA) had Consolidated Net Income/Loss of $-68.33M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$20.87M |
|
$-68.33M |
|
$0.24M |
|
$20.63M |
|
$93.88M |
|
$-73.01M |
|
$4.69M |
|
$-68.32M |
|
$-68.32M |
|
$-68.33M |
|
$-68.33M |
|
|
Consolidated Net Income/Loss |
$-68.33M |
$-68.33M |
|
$-73.01M |
|
$-73.38M |
|
88.86M |
|
88.86M |
|
$-0.77 |
|
$-0.77 |
|
| Balance Sheet Financials | |
$559.44M |
|
$7.59M |
|
$28.35M |
|
$587.79M |
|
$118.19M |
|
$5.57M |
|
$421.17M |
|
$539.36M |
|
$48.43M |
|
$48.43M |
|
$48.43M |
|
88.95M |
|
| Cash Flow Statement Financials | |
$-148.40M |
|
$67.98M |
|
$1.57M |
|
$149.10M |
|
$70.24M |
|
$-78.86M |
|
$16.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.73 |
|
-- |
|
-- |
|
0.10 |
|
0.20 |
|
98.84% |
|
-349.77% |
|
-349.77% |
|
-- |
|
-327.31% |
|
-327.33% |
|
$-149.19M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
0.10 |
|
2.21 |
|
40.73 |
|
-141.08% |
|
-141.08% |
|
-11.62% |
|
-126.52% |
|
$0.54 |
|
$-1.68 |
|
$-1.67 |
|